Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
Blood Research
|
July 4, 2025
SOX4 in chronic lymphocytic leukaemia: the forgotten transcription factor
Ricardo García-Muñoz, Jone Alberdi-Ballina, Giovanna Farfan-Quiroga, et al.
Blood Advances
|
April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
Nancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Leukemia Research
|
December 14, 2011
Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain
Blanca Sanchez-Gonzalez, F Javier Peñalver, Angeles Medina, et al.
Cancer Discovery
|
December 23, 2020
Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death
Vicente Fresquet, Maria J Garcia-Barchino, Marta Larrayoz, et al.
Blood
|
April 13, 2019
PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas
Marién Pascual, María Mena-Varas, Eloy Francisco Robles, et al.
Leukemia & Lymphoma
|
December 6, 2021
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma
Ahmad S Halwani, Carlos Panizo, Iris Isufi, et al.
British Journal of Haematology
|
June 30, 2023
Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study
Ana Muntañola, María Teresa Villalobos, Sonia González-Villambrosia, et al.
Leukemia & Lymphoma
|
August 30, 2021
A randomized phase II study comparing consolidation with a single dose of <sup>90</sup>Y ibritumomab tiuxetan <i>vs.</i> maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Armando López-Guillermo, Miguel Ángel Canales, Ivan Dlouhy, et al.
Lancet (London, England)
|
December 16, 2017
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Michael Wang, Simon Rule, Pier Luigi Zinzani, et al.
Blood
|
January 25, 2020
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
Cecilia Carpio, Reda Bouabdallah, Loïc Ysebaert, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
Blood Research
|
July 4, 2025
SOX4 in chronic lymphocytic leukaemia: the forgotten transcription factor
Ricardo García-Muñoz, Jone Alberdi-Ballina, Giovanna Farfan-Quiroga, et al.
Blood Advances
|
April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
Nancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Leukemia Research
|
December 14, 2011
Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain
Blanca Sanchez-Gonzalez, F Javier Peñalver, Angeles Medina, et al.
Cancer Discovery
|
December 23, 2020
Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death
Vicente Fresquet, Maria J Garcia-Barchino, Marta Larrayoz, et al.
Blood
|
April 13, 2019
PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas
Marién Pascual, María Mena-Varas, Eloy Francisco Robles, et al.
Leukemia & Lymphoma
|
December 6, 2021
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma
Ahmad S Halwani, Carlos Panizo, Iris Isufi, et al.
British Journal of Haematology
|
June 30, 2023
Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study
Ana Muntañola, María Teresa Villalobos, Sonia González-Villambrosia, et al.
Leukemia & Lymphoma
|
August 30, 2021
A randomized phase II study comparing consolidation with a single dose of <sup>90</sup>Y ibritumomab tiuxetan <i>vs.</i> maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Armando López-Guillermo, Miguel Ángel Canales, Ivan Dlouhy, et al.
Lancet (London, England)
|
December 16, 2017
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Michael Wang, Simon Rule, Pier Luigi Zinzani, et al.
Blood
|
January 25, 2020
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
Cecilia Carpio, Reda Bouabdallah, Loïc Ysebaert, et al.
Page
of 6